The site is undergoing maintenance on
Thursday, September 10, 6:00 pm through Friday, September 11, 2:00 am (CEST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance on
Thursday, September 10, 6:00 pm through Friday, September 11, 2:00 am (CEST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance on
Thursday, September 10, 6:00 pm through Friday, September 11, 2:00 am (CEST), 2026
.If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Left Panels - Flow cytometric analysis of CD62L on mouse bone marrow cells. Mouse bone marrow cells were left untreated (Left Panel) or were cultured (1 hour) with Phorbol 12-Myristate 13-Acetate (PMA; Middle Left Panel). The cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with either BD Horizon™ BV786 Rat IgG2a, κ Isotype Control (Cat. No. 563335, dashed line histogram) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Cat. No. 564109, solid line histogram). Fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable bone marrow cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Right Panels - Multicolor flow cytometric analysis of CD62L expression on mouse splenocytes. Mouse splenic leucocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™). The cells were then stained with APC Hamster Anti-Mouse CD3e antibody (Cat. No. 553066/561826) and either BD Horizon BV786 Rat IgG2a, κ Isotype Control (Middle Right Panel) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Right Panel). Two-color flow cytometric contour plots showing the expression of CD62L (or Ig Isotype control staining) versus CD3e were derived from gated events with the forward and side light-scatter characteristics of viable leucocytes. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Left Panels - Flow cytometric analysis of CD62L on mouse bone marrow cells. Mouse bone marrow cells were left untreated (Left Panel) or were cultured (1 hour) with Phorbol 12-Myristate 13-Acetate (PMA; Middle Left Panel). The cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with either BD Horizon™ BV786 Rat IgG2a, κ Isotype Control (Cat. No. 563335, dashed line histogram) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Cat. No. 564109, solid line histogram). Fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable bone marrow cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Right Panels - Multicolor flow cytometric analysis of CD62L expression on mouse splenocytes. Mouse splenic leucocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™). The cells were then stained with APC Hamster Anti-Mouse CD3e antibody (Cat. No. 553066/561826) and either BD Horizon BV786 Rat IgG2a, κ Isotype Control (Middle Right Panel) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Right Panel). Two-color flow cytometric contour plots showing the expression of CD62L (or Ig Isotype control staining) versus CD3e were derived from gated events with the forward and side light-scatter characteristics of viable leucocytes. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Left Panels - Flow cytometric analysis of CD62L on mouse bone marrow cells. Mouse bone marrow cells were left untreated (Left Panel) or were cultured (1 hour) with Phorbol 12-Myristate 13-Acetate (PMA; Middle Left Panel). The cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with either BD Horizon™ BV786 Rat IgG2a, κ Isotype Control (Cat. No. 563335, dashed line histogram) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Cat. No. 564109, solid line histogram). Fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable bone marrow cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Right Panels - Multicolor flow cytometric analysis of CD62L expression on mouse splenocytes. Mouse splenic leucocytes were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™). The cells were then stained with APC Hamster Anti-Mouse CD3e antibody (Cat. No. 553066/561826) and either BD Horizon BV786 Rat IgG2a, κ Isotype Control (Middle Right Panel) or BD Horizon BV786 Rat Anti-Mouse CD62L antibody (Right Panel). Two-color flow cytometric contour plots showing the expression of CD62L (or Ig Isotype control staining) versus CD3e were derived from gated events with the forward and side light-scatter characteristics of viable leucocytes. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
The MEL-14 monoclonal antibody specifically binds to CD62L (L-selectin), a 95 kDa (on neutrophils) or 74 kDa (on lymphocytes) receptor with lectin-like and Epidermal Growth Factor-like domains. In the mouse, L-selectin is detected on most thymocytes, with the highest levels of expression on an immunocompetent subset and a population of dividing progenitor cells, and on peripheral leukocytes, including subsets of B and T lymphocytes, neutrophils, monocytes, and eosinophils. This member of the selectin adhesion molecule family appears to be required for lymphocyte homing to peripheral lymph nodes and to contribute to neutrophil emigration at inflammatory sites. L-selectin is rapidly shed from lymphocytes and neutrophils upon cellular activation; metalloproteinases may mediate the release of CD62L ectodomains from the cell surface. The level of CD62L expression, along with other markers, distinguishes naive, effector, and memory T cells. L-selectin binds to sialytaed oligosaccharide determinants on high endothelial venules (HEV) in peripheral lymph nodes. In vitro studies have demonstrated that CD34, GlyCAM-1, and MAdCAM-1, all recognized by mAb MECA-79 (anti-mouse PNAd Carbohydrate Epitope, Cat. No. 553863), may be ligands for CD62L. MEL-14 mAb blocks in vitro binding of lymphocytes to peripheral lymph node HEV and inhibits in vivo lymphocyte extravasation into peripheral lymph nodes and late stages of leukocyte rolling.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.